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Abstract: A new synthesis of mecamylamine – a known anti-
hypertensive drug with anti-addictive properties is described.  The 
new route allowed access to two novel analogues whose activity 
at two nicotinic acetylcholine receptor subtypes was assessed. 
Addiction is a devastating condition that can result in a 
dramatic loss of life quality for the addict and those closely 
associated with them.  Furthermore it is a considerable driver 
of crime and causes significant burden on the state.  Addiction 
to illicit substances including heroin and cocaine and to legal 
substances nicotine, alcohol and some prescription medications 
are well known.1  Behavioural addictions such as those related to 
gambling have also been documented.1,2  In each addiction, the 
underlying cause is thought to be the highjacking of the reward 
pathway in the CNS which culminates in the release of the 
neurotransmitter dopamine (DA) in the nucleus accumbens (NAc), 
thus producing a feeling of reward.3   
Currently, the only pharmacological agents available to treat 
addiction are related to addiction to nicotine.  The WHO estimates 
that addiction to nicotine and the use of cigarettes as a delivery 
device is responsible for 6 million deaths per year globally with ca. 
one in two smokers dying prematurely of a smoking-related illness.4  
One of the attributes of addiction is that the addict will continue 
with behaviour that is known to be detrimental to their health and 
this is observed in the number of smokers at any given time who 
would like to quit, but are unable to do so.1  The act of smoking 
cessation, or breaking the cycle of addiction associated with any 
addictive substance, is notoriously difficult; resulting in an initial 
period of withdrawal and the continuing problem of remaining 
abstinent for life.  In addition to the use of nicotine replacement 
therapy (gum, lozenges and sprays) two products are currently 
available to assist in smoking cessation.  Varenicline (1- Chantix® 
(US) and Champix® (Europe), Pfizer) is a nicotinic acetylcholine α4β2 
partial agonist and α7 agonist, 5 based on cytisine which has itself 
been used in some jurisdictions to assist smoking cessation.6  
Bupropion (2- Zyban®, GSK) is a repurposed anti-depressant, a 
noradrenaline/dopamine reuptake inhibitor and α3β4 nicotinic 
acetylcholine (nAChR) antagonist (Figure 1).7  Clinical trials have 
indicated that after 12 months smokers using varenicline were a 
little more than twice as likely to be abstinent (22-23%) compared 
to a pharmacologically unassisted placebo attempt (8-10%).  
Varenicline had slightly higher quit-rates than those associated with 
bupropion (15-16%) and varenicline was slightly higher than 
nicotine replacement therapy (NRT) alone.6 Unfortunately, neither 
of these treatments is universally successful and in 2009 the FDA 
required manufacturers of varenicline and bupropion to add boxed 
warnings related to neuropsychiatric disturbances.8 However, these 
treatments do highlight the potential for the exploitation of nAChRs 
via the ventral tegmental area (VTA)-NAc axis for the treatment of 
addictive disorders.  However, there is clearly a need for improved 
pharmacological assistance to facilitate cessation and long term 
abstinence from addictive agents and/or behaviours. 
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Figure 1 – Possible treatments to assist smoking cessation 
Another compound that has stimulated interest in the area and is of 
direct relevance to the work described herein is the general nAChR 
antagonist mecamylamine (3).  Mecamylamine (MA) was initially 
developed as a treatment for hypertension and was sold as 
Inversine® by Merck for many years until the development of β-
blockers which were more effective and have an improved side-
effect profile.9  More recently, interest in mecamylamine has been 
reinvigorated by observations that it has anti-addictive properties 
against not only nicotine but other drugs of abuse.10  For example, 
clinical trials have shown that smokers are more likely to quit and 
more likely to be abstinent after 12 months when assisted by MA in 
combination with NRT - a remarkable 40% remained abstinent after 
12 months.11 MA has been shown to reduce cue-induced craving in 
human cocaine addicts.12  In human clinical studies MA was shown 
to diminish the euphoric and stimulant effects of ethanol  and was 
also found to reduce the self-reported desire to consume ethanol in 
healthy male and female non-smoking social drinkers.13
  
The 
significance of this is enhanced by the fact that, in addition to the 
well known health consequences of excessive alcohol consumption, 
there is growing evidence of a direct link between alcohol intake and 
some cancers.14  MA has been shown to reduce self-administration 
(a model for addiction) of a variety of drugs of abuse such as 
ethanol, opiates and stimulants in animal models.15  There are also 
indications that varenicline may have some role to play in the 
treatment of cocaine addiction.16 
It is currently unknown whether the general activity of MA at 
different nAChR subtypes is important for activity, or indeed 
whether fine-tuning the structure could produce a more effective 
compound by enhancing its activity at a specific receptor subtype;  
α3β415(f) and α4β217 are currently considered prime candidates.  
Moreover, the generation of subtype-specific compounds can help 
elucidate the role of different subtypes within the CNS and offer 
insight into other disorders.18  Surprisingly, despite the long history 
of MA the influence of stereochemistry on activity was only assessed 
in 2001.19  Furthermore, MA seems to have effects in other disorders 
such as Tourette’s Syndrome20
 
and nAChR’s have been postulated to 
have roles in many other neuropsychiatric disorders.18 
 
In addition, MA is an attractive lead for drug development since the 
pharmacokinetics are well understood, bioavailability of MA is high 
and the compound is known to readily cross the blood-brain 
barrier.10  MA has been used by millions of patients which indicates 
that serious side-effects are rare and are typically anti-cholinergic in 
nature e.g. dry mouth and constipation.  Additionally, doses for anti-
addictive action are considerably lower than those required for anti-
hypertensive activity. The work described above indicates that the 
development of analogues merits further investigation.  
 
The seminal SAR studies of MA have been completed by Corne,21 
Stone,22 Wragg,23 Herr24 and Suchocki.25 The key points, of particular 
relevance to this study, are summarised in Figure 2. More recent 
studies by Crookes have developed some interesting dimeric and 
trimeric systems.26   
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Figure 2 – Factors associated with the activity of mecamylamine 
Analysis of the current SAR data highlights two significant points; 
increased steric bulk (for H to Me) at positions 2 and 3 (Figure 2) 
improves activity, and although the bridge is important, the 
relationship of the amine with the 1-carbon and 2-carbon variant 
has not been examined. The current study started with the concept 
of increasing the steric bulk around the amine and also the 
examination of the importance of amine relative stereochemistry. 
Previous syntheses of MA, although concise, have relied on 
camphene derivatives, which meant exploring options other than 
methyl groups adjacent to the amine would be synthetically 
challenging.26,27 In order to explore these options an alternative 
new synthetic route would be required. 
As a model study, the preparation of MA from norboranone (4) was 
attempted – if this methodology were successful it should allow 
alternative groups to be installed in the place of methyl units 
around the amine.  Treatment of norboranone (4) with LDA at low 
temperature gave the expected enolate which was methylated with 
methyl iodide forming 5 in 84% yield.  Note that the addition of the 
electrophile occurred from the exo-face due to the ‘picket fence’ 
effect.28 Attempts to add a second methyl group by treatment with 
LDA and methyl iodide led to incomplete reaction.  However, the 
use of NaHMDS, in place of LDA, followed by treatment with methyl 
iodide generated the dimethylated ketone 6, and exposure of this 
ketone to methyl lithium formed tertiary alcohol 7.  Again the 
‘picket-fence’ effect directed the methyl lithium to the exo-face 
with no evidence of alternative stereoisomers by NMR 
spectroscopy. 
 
Scheme 1 – Formation of the tertiary alcohol 
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The procedure for the conversion of alcohol 7 to azide 8 was based 
on the methodology developed by Arcus29 but required a degree of 
optimisation. Alcohol 7 was exposed to sodium azide in a biphasic 
system consisting of sulfuric acid and chloroform and in this case, 
the reaction was highly dependent on the concentration of sulfuric 
acid employed (Table 1).  Employing 40% sulfuric acid no reaction 
was observed, 50% gave the desired tertiary azide 8 in 67% yield 
while 75% sulfuric acid gave the rearranged product 9.  Presumably, 
during the formation of the desired azide 8 the reaction proceeds 
via a SN1 process with the azide anion adding selectively from the 
exo-face. Azide 8 is relatively volatile and care must be taken when 
removing the solvent at reduced pressure.  
 
Table 1: Formation of azides 8 and 9 
Sulfuric Acid 
Conc. % (M) 
Time 
(h) 
Product Distribution (%) 
7                 8                9 
75 (13.8)  3 0 0 100 
50 (9.2) 4 0 100 0 
40 (7.4) 24 100 0 0 
 
Reduction of the azide 8 also proved interesting.  Initially the 
reduction was attempted using typical Staudinger Reaction 
conditions,30 with triphenylphosphine and water in THF at room 
temperature however, this was unsuccessful.  Repeating the 
reaction in toluene at reflux was also failed to provide any of the 
desired amine.  Vaultier31 has shown that, in the case of hindered 
azides, it can be beneficial to complete the formation of the 
intermediate iminophosphorane prior to the addition of water.  
Treatment of the azide 8 with triphenylphosphine in toluene at 
reflux formed a new synthetic intermediate (R1 = Ph, indicated by 
31P NMR) but the expected amine was not produced upon addition 
of water, instead the intermediate slowly reverted back to the 
starting azide 8.  This indicated that the intermediate observed was 
not the expected iminophosphorane as diatomic nitrogen gas 
would be lost, irreversibly, in the process of its formation.  It is 
known that tributylphosphine is more reactive than 
triphenylphosphine in the Staudinger Reaction32 and it was 
employed in this case.  Treatment of azide 8 with tributylphosphine 
in THF generated a new product (presumably phophoazide 10, R1 = 
Bu, indicated by 31P NMR) after 4 hours at room temperature. 
Addition of water followed by treatment with 2M HCl in diethyl 
ether provided the expected amine salt 14.HCl.  Formation of the 
HCl salt allowed simple removal of tributylphosphine oxide by 
washing with butanone.  Treatment with aqueous NaOH gave the 
expected amine 14 in 58% yield. 
 
Scheme 2 – Azide reduction 
During the Staudinger Reaction with tributylphosphine it was noted 
that only upon addition of water was a gas (presumably nitrogen) 
evolved.  It was therefore speculated that the highly congested 
bicyclic system in combination with the bulky phosphines formed 
intermediates that were unable to undergo the standard 
Staudinger-type mechanism and that the reaction therefore stalled 
at the phosphoazide intermediate 10.  In the case of the 
tributylphosphine we suggest that the added water is able to bridge 
the cis-phosphoazide 12 and effect the loss of nitrogen without the 
requirement for a formal formation of a 4-membered ring.  In the 
case of the triphenyl derivative, it is suspected that the 
intermediate is too hindered and/or electronically unreactive for 
water to have the same effect providing a means for the 
phosphoazide (10, R1 = Ph)  to revert back to the azide 8.  Attempts 
at aza-Wittig reactions from either of the initial phosphine addition 
products (prior to the addition of water, usually expected to be the 
iminophosphorane) were unsuccessful. 
Although the Staudinger Reaction was attractive from the 
perspective of functional group compatibility, allowing access to 
more elaborate analogues for future SAR work, other reduction 
methodologies were also explored (Scheme 3).  Treatment of azide 
8 with 10% Pd/C and hydrogen produced the amine 14 in 90% yield 
and treatment with lithium aluminium hydride provided the 
expected compound 14 in 70% yield.   
 
Scheme 3 – Alternative azide reduction. 
Reductive amination allowed the successful addition of a methyl 
group to 14 after problems associated with dimethylation were 
solved by a slightly modified procedure.  The reaction of amine 14 
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with paraformaldehyde in dichloromethane was monitored by 
proton NMR spectroscopy until complete formation of the imine 
had occurred at which point sodium borohydride was added 
followed by the dropwise addition of methanol which gave MA (3) 
in 72% yield (Scheme 4).  It was important to add a limited quantity 
of methanol, dropwise, to prevent decomposition of the imine.  
Alternatively, deprotonation of amine 14 with butyl lithium before 
the addition of methyl iodide gave MA in 49% yield.  
 
Scheme 4 – Methylation to form mecamylamine 
Having prepared MA itself attention turned to the synthesis of 
endo-MA (17) in which the amine is positioned on the same face as 
the two-carbon bridge (Scheme 6).  The synthetic approach 
involved attack of a nucleophile on the appropriate imine 16, 
hopefully controlled by the picket fence effect; the first task was to 
prepare the hindered imine.  Although the synthesis of endo-MA 
(17) has been reported by Suchocki25 it was formed in trace 
quantities (<1%) that only permitted characterisation by mass 
spectral analysis. Rather than employ the same method of imine 
formation (which required bubbling methyl amine through a 
reaction mixture in toluene at reflux for 18 hours) we employed the 
methodology developed by Moss (Scheme 5).33 The reaction was 
performed in a sealed system, and the order of reagent addition 
proved critical. DBU was added to a suspension of methylamine 
hydrochloride and stirred until the mixture became homogeneous.  
Titanium tetrachloride and trimethylamine were added sequentially 
and the mixture heated at reflux for 20 minutes before the ketone 6 
was added and heating continued for 16 hours.  After work-up the 
hindered imine 16 was recovered in 61% yield. 
 
Scheme 5 – Formation of a hindered imine 
Treatment of the imine 16 with methyl lithium, methylmagnesium 
bromide or methylcerium trichloride gave none of the desired 
amine.  However, precomplexation with borontrifluoride etherate 
to form a solid prior to addition of 10 equivalents of methyl lithium 
in diethyl ether gave endo-MA (17) in 56% yield after work-up with 
concentrated ammonia (Scheme 6). 
 
Scheme 6 – Preparation of endo-mecamylamine 
Having developed a new synthetic route to MA and having 
prepared endo-MA (17) in sufficient quantities for analysis and 
biological evaluation, the versatility of the new synthetic approach 
was investigated further.  Previous SAR work had shown that the 
replacement of hydrogen with methyl groups around the amine 
gave improved activity.  It was decided to examine the effect of 
adding further steric bulk with the exchange of one of the methyl 
groups for an ethyl group.  It was hoped that the “picket-fence” 
effect28 could be used to control the addition of nucleophiles and 
electrophiles to the exo-face, at least during the early stages of the 
synthetic sequence.  Fortunately this was indeed the case and the 
two deprotonation/alkylation steps with the appropriate 
electrophiles gave ketone 18 in 68% yield (Scheme 7). Subsequent 
nucleophilic attack of methyllithium gave alcohol 19 in 92% yield.  
All reactions occurred diastereoselectively from the exo-face, with 
no indication (by NMR spectroscopy) of the formation of alternative 
stereoisomers. 
 
Scheme 7 – Replacing a methyl group with ethyl 
The formation of azide 20 was achieved by treatment of alcohol 19 
with sodium azide in a biphasic solvent system with sulfuric acid  
and chloroform (Scheme 8).  Once again, use of 9.2M (50%) sulfuric 
acid facilitated the formation of the desired azide in 53% yield 
without the concomitant formation of the azide formed by the 
Wagner-Meerwein-type rearrangement.  However, in this reaction 
a second azide was formed in 28% yield that appeared to be lacking 
an ethyl group and was tentatively assigned as 21.  
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Scheme 8 – Azide formation 
Attempts to reduce the azide by catalytic hydrogenation led to 
decomposition however, fortunately, treatment with LiAlH4 in 
THF at 0 ºC gave the expected amine 22 in 84% yield (Scheme 
9). 
 
 
Scheme 9 – Azide reduction 
The final step was the methylation of the amine and the two-
step reductive amination methodology was employed once 
again (Scheme 10).  The reaction of amine 22 with 
paraformaldehyde in dichloromethane was monitored by 
proton NMR spectroscopy until complete formation of the 
imine 23 had occurred at which point sodium borohydride was 
added followed by the dropwise addition of methanol which 
gave the MA derivative 24 in 59% yield. 
 
 
Scheme 10 – Formation of a mecamylamine analogue 
 
Having prepared mecamylamine and two novel analogues all three 
compounds were evaluated by assessing their ability to reduce the 
action of agonists at two nAChR subtypes.  In order to gain 
preliminary insight into the effects of the structural alterations the 
compounds were tested at fixed concentrations against the α4β2 
subtype (expressed in oocytes, 3 μM vs ACh 100 μM) and the α3β4 
subtype (SH-SY5Y cells, 100 μM vs nicotine 100 μM).  Interestingly, 
endo-MA (17, entry 3 of table 2) was more active than MA (3, entry 
2 of Table 2) at α4β2 but less active than MA (3) at α3β4.  Compound 
24 (entry 4 of Table 2) had a similar profile and was more active 
than MA (3) at α4β2 but less active then MA (3) at α3β4. Pleasingly, 
the preliminary pharmacological data indicate that manipulation of 
the structure will allow the enhancement of both activity and 
selectivity, at least in the case of the α4β2receptor, and work will 
continue to develop compounds that are more selective for the 
α3β4 receptor. 
Table 2 – Biological activity of the parent compound exo-mecamylamine and two 
new analogues 
 
Entry  Compound α4β2 response (%) α3β4 response (%) 
1 -- 100 100 
2 3.HCl 33 ± 8% 6.3 ± 1% 
3 17.HCl 18 ± 7% 13.8 ± 7% 
4 24.HCl 18 ± 5% 12.0 ± 2% 
 
Conclusions 
A new route to mecamylamine and mecamylamine analogues 
which allowed the facile synthesis of MA itself and two 
analogues is described.  Preliminary pharmacological 
evaluation of the simple MA derivatives indicates that minor 
structural changes e.g. methyl to ethyl have interesting effects 
on activity at nAChR subtypes.  Of particular note is the fact 
that these small structural changes show enhanced selectivity 
and activity at the two subtypes assessed.  The versatile route 
should allow installation of a variety of functional groups 
which is significant in light of the biological effect of the simple 
structural modifications described.  Clearly more detailed 
pharmacology is required but the work reported herein 
indicates that the formation of analogues related to MA may 
be fruitful in the pursuit of effective treatments and/or tool 
compounds for addiction and other psychiatric disorders 
associated with nAChRs.  
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 Experimental procedure 
 
  General Experimental section 
 
 Melting points were determined using a standard melting 
point apparatus and are uncorrected.  Infrared spectra were 
obtained on a Perkin Elmer Spectrum 100 FT-IR 
spectrometer equipped with a universal ATR sampling 
accessory.  Proton nuclear magnetic resonance (NMR) 
spectra were recorded on: Bruker Avance III 400 MHz, Bruker 
DPX400 400 MHz and Bruker Avance II 600 MHz 
spectrometers (1H NMR spectra were recorded at 400.23 
MHz, 400.13 MHz and 600.13 MHz respectively).  Chemical 
shifts are reported in ppm relative to tetramethylsilane and 
coupling constants (J) are quoted in Hertz.  Carbon NMR 
spectra were recorded on the previously mentioned 
instruments (100.64 MHz, 100.61 MHz & 150.9 MHz, 
respectively) with total proton decoupling.  HSQC, HMBC, 
TOCSY and nOe NMR experiments were used to aid 
assignment of NMR peaks when required.  A Waters 
micromass LCT-tof mass spectrometer was used in ES 
positive and ES negative modes for electrospray mass 
spectrometry.  Electron impact mass spectra were 
determined on a Quatro-II mass spectrometer in the EI 
mode.  Mass spectra were recorded in CSCB Trinity College 
Dublin, CSCB University College Dublin.  Flash 
chromatography was performed using Merk Kiesegel 60 (art. 
9385).  Merck precoated Kiesegel foils 60F254 were used for 
thin-layer chromatography and slides were visualised by UV 
irradiation, KMnO4, or anisaldehyde staining.  Toluene, 
CH2Cl2, and triethylamine were distilled from calcium 
hydride. 
1  
 3-exo-Methylbicyclo[2.2.1]heptan-2-one (5) 
2  
 
 
3 A solution of freshly distilled diisopropylamine (1.70 mL, 1.72 
g, 11.84 mmol) in anhydrous THF (11 mL) was cooled to -78 
oC, a solution of  2.5 M n-butyllithium in hexanes (4.60 mL, 
11.36 mmol) was added. The reaction mixture was allowed 
to warm to 0 ºC and a solution of bicyclo[2.2.1]heptan-2-one 
(1.00 g, 9.08 mmol) in anhydrous THF (2 mL) was then added 
dropwise. After stirring for 2 hours at 0 oC, iodomethane 
(1.70 mL, 3.87 g, 27.30 mmol) was added dropwise. After 
stirring for 2 hours at room temperature, a solution of 1M 
HCl (8 mL) was added. The product was extracted using 
diethyl ether (2 x 10 mL), washed with brine (10 mL) and 
dried over MgSO4. The solvent was evaporated at reduced 
pressure to yield the title compound as a yellow oil. (0.95g, 
84%) 
4  
5 IR υmax (cm
-1):  2956, 2874, 1736, 1459, 1082, 937, 850. 
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6 1H NMR (CDCl3, 400 MHz): δ (ppm) 1.06 (d, J = 7.5 Hz, 3H, 
H8), 1.43-1.56 (m, 3H, H5a, H6a, H7a), 1.77-1.91 (m, 4H, H5b, 
H6b, H3, H7b), 2.30-2.35 (m, 1H, H4), 2.53-2.58 (m, 1H, H1). 
7 13C NMR (CDCl3, 100 MHz): δ (ppm)  13.7 (CH3, C8), 23.3 
(CH2, C6), 27.5 (CH2, C5), 34.0 (CH2, C7), 41.0 (CH, C3), 47.5 
(CH, C4), 49.2 (CH, C1), 220.7 (q, C2). 
8 HRMS: (m/z - CI) calcd. for C8H13O (M+H)
+ 125.0966, found 
125.0974. 
9  
 3,3-Dimethylbicyclo[2.2.1]heptan-2-one (6) 
10  
11  
12 General procedure A 
13 A solution of 3-exo-methylbicyclo[2.2.1]heptan-2-one (1.24 
g, 10 mmol) in anhydrous THF (12 mL) was added to a cooled 
(-78 ºC) 1M solution of sodium bis(trimethylsilyl)amide in 
THF (15.00 mL, 15.00 mmol) and the reaction mixture 
allowed to warm to 0 ºC. After stirring for 2 hours at 0 ºC, 
iodomethane (1.93 mL, 4.40 g, 30.98 mmol) was added 
dropwise and the reaction mixture allowed to warm to room 
temperature. After stirring for 2 hours at room temperature, 
a solution of 1M HCl (8 mL) was added. The product was 
extracted using diethylether (2 x 10 mL), washed with brine 
(10 mL) and the combined organic extracts dried over 
MgSO4. The solvent was evaporated at reduced pressure to 
provide a pale yellow oil which was purified by flash 
chromatography on silica gel eluting with 97:3 
hexane:ethylacetate to yield the title compound as a pale 
yellow oil. (1.15g, 83%) 
14  
15 IR υmax (cm
-1): 2967, 2874, 1739, 1464, 1290, 1153, 949, 748. 
16 1H NMR (CDCl3, 400 MHz): δ (ppm) 1.04 (s, 3H, H9), 1.08 (s, 
3H, H8), 1.43-1.53 (m, 2H, H6a, H7a), 1.58-1.72 (m, 1H, H5a), 
1.76-1.93 (m, 2H, H5b, H6b), 1.97-2.03 (m, 1H, H7b), 2.30-
2.35 (m, 1H, H4), 2.53-2.58 (m, 1H, H1). 
17 13C NMR (CDCl3, 100 MHz): δ (ppm) 21.5 (CH3, C9), 23.26 
(CH3, C8), 23.31 (CH2, C5), 24.6 (CH2, C6), 35.1 (CH2, C7), 46.2 
(CH, C4), 47.2 (q, C3), 50.2 (CH, C1), 223.3 (q, C2). 
18 HRMS: (m/z-EI) calcd. for C9H14O (M)
+ 138.1045, found 
138.1045. 
19  
 2-exo-,3,3-Trimethylbicyclo[2.2.1]heptan-2-ol (7) 
20  
21  
 
22 General procedure B 
23 A solution of 3,3-dimethylbicyclo[2.2.1]heptan-2-one (0.897 
g, 6.50 mmol) in anhydrous THF (20 mL) was added dropwise 
to a cooled (-78 ºC) solution of methyllithium (1.6 M in 
diethylether, 8.13 mL, 13.00 mmol). The reaction mixture 
was allowed to warm to room temperature and after 3 
hours, 10% aqueous NH4Cl (20 mL) was added. The product 
was extracted using diethylether (2 x 20 mL), washed with 
brine (20 mL) and the combined organic extracts dried over 
MgSO4. The solvent was evaporated at reduced pressure to 
yield a pale yellow oil which was purified by flash 
chromatography on silica gel eluting with 98:2 hexane:ethyl 
acetate to give the title compound as a white solid (0.89g, 
89%). M.p. 118-120 oC (lit.,34 113-115oC) 
24  
25 IR υmax (cm
-1): 3411, 2929, 2871, 1473, 1371, 1295, 1087, 927 
26 1H NMR (CDCl3, 400 MHz):  δ (ppm) 0.94 (s, 3H, H9), 0.97 (s, 
3H, H8), 1.19-1.15 (m, 1H, H7a), 1.25 (s, 3H, H10), 1.27-1.36 
(m, 3H, H5a, H6a, H11), 1.71-1.78 (m, 3H, H7s, H4, H6b), 
1.85-1.90 (m, 1H, H5b), 1.97-2.01 (m, 1H, H1) 
27 13C NMR (CDCl3, 100 MHz): δ (ppm) 21.1 (CH2, C5), 21.8 
(CH3, C9), 24.0 (CH2, C6), 26.3 (CH3, C10), 27.0 (CH3, C8), 34.6 
(CH2, C7), 42.0 (q, C3), 49.7 (CH, C4), 50.9 (CH, C1), 78.8 
(q,C2). 
28 HRMS: (m/z - EI) calcd. for C10H6O4N2S (M)
+ 154.1358, found 
154.1353. 
29  
 2-Azido-2-endo-,3,3,-trimethyl-bicyclo[2.2.1]heptane (8) 
30   
31  
32  
33 General Procedure C 
34 A solution of HN3 was prepared by carefully adding a solution 
of 50% aqueous H2SO4 (10 mL) to NaN3 (2.00 g, 30.77 mmol) 
in CHCl3 (50 mL) at 0 ºC. To this was added 2,3,3-
trimethylbicyclo[2.2.1]heptan-2-ol (1.00 g, 6.49 mmol). After 
stirring for 4 hours at room temperature, ice-cold water (30 
mL) was added. The product was extracted with CH2Cl2 (3 x 
30 mL). The combined organic extracts were washed with 5% 
NaHCO3 solution (30 mL), dried over MgSO4, and evaporated 
at reduced pressure to give a yellow oil which was purified 
by flash chromatography on silica gel using 100% hexane to 
yield the title compound as pale yellow oil. (0.78 g, 67% 
yield) 
35  
36 IR υmax (cm
-1): 2934, 2876, 2083, 1454, 1253, 1071, 801 
37 1H NMR (CDCl3, 400 MHz): δ (ppm) 0.94 (s, 3H, H9), 1.06 (s, 
3H, H8), 1.12-1.16 (m, 1H, H7a), 1.25-1.35 (m, 4H, H10, H5a), 
1.41-1.51 (m, 2H, H6), 1.55-1.63 (m, 1H, H5b), 1.75-1.80 (m, 
1H, H4), 1.99-2.05 (m, 1H, H7b), 2.11-2.15( m, 1H, H1). 
38 13C NMR (CDCl3, 100 MHz): δ (ppm) 17.3 (CH3, C10), 23.1 
(CH2, C6), 23.5 (CH3, C9), 23.7 (CH2, C5), 26.8 (CH3, C8), 34.8 
(CH2, C7), 43.9 (q, C3), 48.8 (CH, C1), 49.8 (CH, C4), 72.6 (q, 
C2). 
39 HRMS: (m/z - ES) calcd. for C10H18N (M+H-N2)
+ 152.1439, 
found 152.1443. 
40  
 2-endo-,3,3-Trimethyl-bicyclo[2.2.1]heptan-2-amine (14) 
41  
42  
43  
44 Reduction using lithium aluminium hydride:  
45 General procedure D 
46 To a solution of 2-azido-2-endo-,3,3-
trimethylbicyclo[2.2.1]heptane (179 mg, 1 mmol) in 
anhydrous THF (10 mL) under an argon atmosphere cooled 
to 0 ºC, was added a solution of lithium aluminium hydride 
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(2M in THF, 400 µL, 0.80 mmol) dropwise. The reaction 
mixture was allowed to warm to room temperature over 2 
hours. After this time, TLC analysis showed that no starting 
material remained. The reaction mixture was cooled to 0 ºC 
and 2 M NaOH (10 mL) was added slowly. After stirring for 
30 minutes at room temperature, the product was extracted 
using diethyl ether (2 x 10 mL), washed with brine (10 mL), 
the combined organic extracts dried over MgSO4 and 
concentrated to give a clear viscous oil. The crude oil was 
further purified by flash chromatography on silica gel eluting 
with 50:50 hexane:ethyl acetate to provide the title 
compound (107 mg, 70%) M.p. 110 oC -112 oC (Sublimes) 
47  
48 Reduction via Staudinger protocol: 
49  
50 To a solution of 2-azido-2-endo-,3,3-
trimethylbicyclo[2.2.1]heptane (179mg, 1 mmol) in 
anhydrous THF (10 mL) under an argon atmosphere, 
tributylphosphine (375 µL, 304 mg, 1.5 mmol) was added. 
The reaction mixture was stirred for 4 hours at room 
temperature. H2O (180 µL, 10 mmol) was added and 
effervescence was observed. The reaction mixture was 
stirred for a further 16 hours at room temperature. The 
organic solvent was evaporated to yield a pale yellow oil. 
This oil was redissolved in DCM (20 mL) and dried over 
MgSO4. A 2 M solution of hydrogen chloride in diethyl ether 
(1 mL, 2 mmol) was added to form the hydrochloride salt of 
the amine that was triturated to give a pale yellow oil that 
was purified by flash chromatography on silica gel using a 
eluent gradient from 100% ethyl acetate to 50:50 ethyl 
acetate:methanol. After removing the solvent under 
vacuum, the amine was extracted from 1M NaOH (15 mL) 
using CH2Cl2 (2 x 15 mL), dried over MgSO4, filtered and 
concentrated to yield the title compound (88 mg, 58%) M.p. 
110 oC -112 oC (Sublimes)  
51  
52 Reduction by hydrogenation: 
53  
54 To a solution of 2-azido-2-endo-3,3-trimethyl-
bicyclo[2.2.1]heptane (0.30 g, 1.72 mmol), in methanol (20 
mL) palladium on charcoal (0.03 g, 10% w/w) was added. The 
reaction vessel was evacuated and filled with hydrogen. The 
reaction mixture was stirred vigorously under a blanket of 
hydrogen at atmospheric pressure overnight. The reaction 
mixture was filtered through celite, dried over magnesium 
sulfate and filtered before the volatiles were removed at 
reduced pressure. The free amine was isolated by the 
addition of a 1M solution of NaOH and extraction with ethyl 
acetate (2 x 20 mL).  The combined organic extracts were 
dried over magnesium sulfate and filtered before the 
volatiles were removed at reduced pressure to yield the title 
compound as a white solid (0.24 g, 1.56 mmol, 90%). M.p. 
110 oC -112 oC (Sublimes).  
 
55 IR υmax (cm
-1): 3387, 2953, 2870, 1464, 1386, 1258, 1127, 
806, 743. 
56 1H NMR (CDCl3, 400 MHz): δ (ppm) 0.93 (3H, s, H8), 1.00 
(3H, s, H9), 1.07-1.13 (4H, m, H10, H7a), 1.23-1.33 (1H, m, 
H5a), 1.33-1.43 (1H, m, H6a), 1.50-1.66 (2H, m, H5b, H6b), 
1.71-1.76 (1H, m, H1), 1.80-1.85 (1H, m, H4), 1.91-1.97 (1H, 
m, H7b). 
57 13C NMR (CDCl3, 100 MHz): δ (ppm) 22.8 (C10), 23.0 (C6), 
23.1 (C8), 23.6 (C5), 25.9 (C9), 34.0 (C7), 42.5 (q, C3), 49.9 
(C1), 52.1 (C4), 59.5 (q, C2). 
58 HRMS:   (m/z - EI) Calculated for C10H19N (M)
+ 153.1517, 
found 153.1510. 
59  
 2-endo-3,3-Trimethyl-N-methylenebicyclo[2.2.1]heptan-2-
amine (15) 
60  
61  
62  
General Procedure E 
To a solution of 2-endo-,3,3-trimethyl-bicyclo[2.2.1]heptan-
2-amine (1.00 g, 6.54 mmol) in anhydrous DCM (20 mL), 
under an argon atmosphere, was added paraformaldehyde 
(1.18 g, 39.25 mmol) and 4Å molecular sieve pellets (1 g). 
The reaction mixture was heated at reflux under an argon 
atmosphere until NMR indicated complete formation of the 
imine (ca. 12 h). After this time, the molecular sieves and any 
unreacted paraformaldehyde were removed by filtration. 
The residue was washed with DCM (40 mL). The washings 
were combined and the solvent evaporated at reduced 
pressure to yield the title compound as a clear oil (0.98g, 
91%) that was used in the next step without further 
purification. 
63  
IR υmax (cm
-1):  2934, 2867, 1647, 1460, 1095, 937, 782, 
1386, 1290, 1075, 971, 878 
1H NMR (CDCl3, 400 MHz): δ (ppm) 0.88 (s, 3H, H9), 0.94 (s, 
3H, H8), 1.06 (s, 3H, H10), 1.09-1.13 (m, 1H, H7a), 1.32-1.40 
(m, 1H, H5a), 1.42-1.50 (m, 1H, H6a), 1.53-1.63 (m, 1H, H6b), 
1.65-1.74 (m, 1H, H5b), 1.77-1.82 (m, 1H, H4), 2.02-2.12 (m, 
2H, H1, H7b), 7.32-7.45 (m, 2H, H11). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 18.3 (CH3, C10), 23.1 
(CH3, C8), 23.3 (CH2, C6) 23.57 (CH3, C9), 23.62 (CH2, C5), 
27.6 (CH3, C9), 33.9 (CH2, C7), 43.2 (q, C3), 48.7 (CH, C4), 49.7 
(CH, C1), 70.1 (q, C2), 146.5 (CH2, C11). 
64   
 N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine (3) 
65  
66  
67  
68  
General Procedure E 
2-endo-3,3-trimethyl-N-methylenebicyclo[2.2.1]heptan-2-
amine (1.00 g, 6.06 mmol) was added to NaBH4 (345 mg, 
9.09 mmol) in anhydrous DCM (20 mL), under an argon 
atmosphere, at -78 ºC. Anhydrous methanol (0.97 mL, 30.6 
mmol) was added dropwise and the reaction mixture 
allowed to warm to room temperature. After 1 hour, water 
(20 mL) was added and the product was extracted using 
DCM (2 x 20 mL). The organic extracts were combined and 
dried over MgSO4. The solvent was removed under reduced 
pressure to yield the title compound as a clear oil (0.82 g, 
81%). The product was dissolved in anhydrous diethyl ether 
(8 mL) and a solution of hydrogen chloride (2 M in diethyl 
ether, 4.0 mL, 8.0 mmol) was added, the resultant solid  was 
isolated by filtration and dried under vacuum to yield the 
expected hydrochloride salt compound as a white solid in 
quantitative yield.  M.p. 239 ºC -241 ºC (decomposes), litt22 
245 ºC -246 ºC. 
69  
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Alkylation via quantitative deprotonation and subsequent 
alkylation: 
 
A solution of n-butyllithium (2.5M in hexanes, 222 µL, 0.56 
mmol) in anhydrous THF (2 mL) was prepared and cooled to 
0 ºC. To this was added a solution of 2-endo-,3,3-trimethyl-
bicyclo[2.2.1]heptan-2-amine (0.081 g, 0.53 mmol) in 
anhydrous THF (1 mL) dropwise. The reaction mixture was 
cooled to -78 ºC before freshly distilled iodomethane (34 µL, 
0.57 mmol) was added dropwise and the reaction mixture 
allowed to warm to room temperature over 30 minutes. 
Water (10 mL) was added and the product was extracted 
with DCM (2 x 20 mL). The organic extracts were combined 
and dried over MgSO4. The solvent was evaporated at 
reduced pressure to yield the title compound as a clear oil 
(0.44 g, 49 %). 
 
N,2-endo-,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine (3) 
 
IR υmax (cm
-1): 2930, 2830, 1450, 1410, 1255, 1110 
1H NMR (CDCl3, 400 MHz): δ (ppm) 0.95 (s, 3H, H9), 1.01-
1.05 (m, 4H, H8, H7a), 1.06 (s, 3H, H10), 1.23-1.32 (m, 1H, 
H5a), 1.33-1.47 (m, 2H, H6), 1.52-1.65 (m, 1H, H5b), 1.65-
1.70 (m, 1H, H1), 1.82-1.90 (m, 1H, H7b), 2.17-2.22 (m, 1H, 
H4), 2.31 (s, 3H, H11). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 17.5 (CH3, C10), 22.9 
(CH2, C6), 23.1 (CH3, C9), 23.7 (CH2, C5), 25.1 (CH3, C8), 29.7 
(CH3, C11), 33.9 (CH2, C7), 43.4 (q, C3), 44.5 (CH, C4), 50.0 
(CH, C1), 63.3 (q, C2). 
HRMS: (m/z - ES) calcd. for C11H22N (M+H)
+ 168.1747, found 
168.1752.  
 
N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-aminium chloride 
(3.HCl) 
 
IR υmax (cm
-1): 2933, 1594, 1462, 1387, 1112, 1071. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 1.00 (s, 3H, H9), 1.19-
1.25 (d, J = 12.3 Hz, 1H, H7a), 1.28 (s, 3H, H8), 1.30-1.37 (m, 
1H, H5a), 1.38-1.50 (m, 5H, H10, H6), 1.51-1.61 (m, 1H, H5b), 
1.82-1.85 (m, 1H, H4), 2.34-2.43 (m, 2H, H1, H7b), 2.59-2.69 
(m, 3H, H11), 8.40 (bs, 1H, H12), 9.05 (bs, 1H, H12). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 16.1 (CH3, C10), 22.9 
(CH2, C6), 23.3 (CH3, C9), 23.4 (CH2, C5), 26.2 (CH3, C8), 28.9 
(CH3, C11), 34.5 (CH2, C7), 44.6 (q, C3), 44.9 (CH, C4), 50.5 
(CH, C1), 70.1 (q, C2). 
HRMS: (m/z - ES) calcd. for C11H22N M
+ 168.1747, found 
168.1741. 
 
70  
 N-(3,3-Dimethylbicyclo[2.2.1]heptan-2-ylidene) 
methanamine (16). 
71  
72  
73  
Methylamine hydrochloride (640 mg, 9.48 mmol) was 
ground into a fine powder and heated to 100 ºC under high 
vacuum to remove all traces of water. A reflux condenser 
was fitted to the flask and the system flushed with argon and 
a thick septum added. 1,8-Diazabicyclo[5.4.0]undec-7-ene 
(19.24 mmol, 1.406 mL, 1.434 g) was added and the reaction 
mixture stirred for 5 minutes. Triethylamine (4.545 mL, 3.30 
g, 32.61 mmol) was added. Titanium tetrachloride solution (1 
M in DCM, 3.60 mL, 3.60 mmol) was added and the reaction 
was stirred for 20 minutes at 40 ºC. 3,3-
dimethylbicyclo[2.2.1] heptan-2-one (1.00 g, 7.25 mmol) was 
added slowly and the reaction mixture turned from bright 
red to dark brown. After stirring at 40 ºC for 16 hours, the 
reaction mixture was poured into diethyl ether (200 mL) and 
filtered thorough celite to remove triethylamine 
hydrochloride. The organic fraction was dried over MgSO4 
and evaporated at reduced pressure to yield the title 
compound as a clear oil (663 mg, 61%) which was employed 
in the next step without further purification. 
74  
IR υmax (cm
-1): 2965, 2869, 1686, 1463, 1379, 1105, 1066. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 1.08 (s, 3H, H9), 1.09 (s, 
3H, H8), 1.23-1.33 (m, 1H, H6a), 1.41-1.46 (m, 1H, H7a), 1.53-
1.63 (m, 1H, H5a), 1.74-1.88 (m, 3H, H5b, H6b, H7b), 2.08-
2.11 (m, 1H, H4), 3.11 (s, 3H, H10), 3.19-3.24 (m, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 22.6 (CH3, C9), 22.9 
(CH2, C5), 24.6 (CH2, C6), 24.7 (CH3, C8), 35.4 (CH2, C7), 38.3 
(CH3, C10), 40.1 (CH, C1), 44.3 (q, C3), 46.8 (CH, C4), 189.8 (q, 
C2). 
HRMS: (m/z - ES) calcd. for C10H18N (M+H)
+ 152.1439, found 
152.1444. 
75  
 N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-aminium 
chloride (17.HCl). 
76  
77  
78  
N-(3,3-Dimethylbicyclo[2.2.1]heptan-2-ylidene) 
methanamine (250 mg, 1.66 mmol) was placed in a RBF with 
a stirring bar in the absence of any solvent under an argon 
atmosphere. To this was added boron trifluoride diethyl 
etherate (316 µL, 354 mg, 2.49 mmol) dropwise and a 
crystalline solid formed. The reaction mixture was cooled to 
0 ºC and methyllithium solution (1.6 M in diethyl ether, 
10.00 mL, 16.00 mmol) was added dropwise. The reaction 
mixture was allowed to warm to room temperature and 
stirred for 1 hour. Ammonium hydroxide solution (30% in 
water, 10 mL was added and the product extracted with 
diethyl ether (2 x 10 mL), washed with brine (10 mL) and the 
combined organic extracts dried over MgSO4. The volatiles 
were removed at reduced pressure to yield the desired 
amine as a viscous oil. This product was redissolved in 
anhydrous diethyl ether (2 mL) and a solution of hydrogen 
chloride (2 M in diethyl ether, 1.0 mL, 2.0 mmol) was added. 
The hydrochloride salt was isolated by filtration and dried 
under vacuum to yield the title compound as a white solid 
(191 mg, 56%). M.p. 140 ºC -145 ºC (decomposes). 
79  
IR υmax (cm
-1): 3358, 2965, 1457, 1381, 1341, 1081, 912. 
1H NMR (d6-DMSO, 400 MHz): δ (ppm) 1.00 (s, 3H, H8), 
1.11-1.23 (m, 4H, H7a, H9), 1.24 (s, 3H, H10), 1.30-1.47 (m, 
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2H, H5a, H6a), 1.50-1.68 (m, 2H, H5b, H6b), 1.73-1.77 (m, 
1H, H4), 1.82-1.89 (m, 1H, H7b), 2.14-2.18 (m, 1H, H1), 2.47 
(t, J = 5.34 Hz, 3H, H11), 7.91 (br s, 1H, H12a), 9.25 (br s, 1H, 
H12b). 
13C NMR (d6-DMSO, 100 MHz): δ (ppm) 19.1 (CH3, C10), 
21.8 (CH3, C9), 21.8 (CH2, C6), 23.4 (CH2, C5), 27.5 (CH3, C8), 
28.9 (CH3, C11), 34.7 (CH2, C7), 42.9 (q, C3), 46.4 (CH, C1), 
49.7 (CH, C4), 68.4 (q, C2). 
HRMS: (m/z - ES) calcd. for C11H22N (M
+) 168.1752, found 
168.1751. 
80  
3-exo-Ethyl,3-methylbicyclo[2.2.1]heptan-2-one (18) 
81  
82   
83  
Prepared as per general Procedure A using 3-exo-
methylbicyclo[2.2.1]heptan-2-one (1.76 g, 14.20 mmol), 1 M 
sodium bis(trimethylsilyl)amide in THF (21.3 mL, 21.3 mmol), 
THF 25 mL and iodoethane (3.41 mL, 6.65 g, 42.62 mmol) to 
yield the title compound as a clear oil. (1.75 g, 81%). 
84  
IR υmax (cm-1): 2960, 2876, 1739, 1460, 1083, 938, 850. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 0.89 (t, J = 7.2 Hz, 3H, 
H9), 0.97 (s, 3H, H10), 1.33-1.53 (m, 4H, H6a, H7a, H8), 1.56-
1.66 (m, 1H, H5a), 1.68-1.77 (m, 1H, H5b), 1.79-1.90 (m, 1H, 
H6b), 1.93-2.01 (m, 1H, H7b), 2.36 (br s, 1H, H4), 2.52-2.57 
(m, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 8.4 (CH3, C10), 17.9 
(CH3, C9), 23.2 (CH2, C5), 25.2 (CH2, C6), 34.8 (CH2, C7), 42.8 
(CH, C4), 50.1 ( q, C3), 50.2 (CH, C1), 223.3 (q, C2). 
HRMS: (m/z - ES) calcd. for C10H17O (M
+) 153.1279, found 
153.1279. 
85  
3-exo-Ethyl-2-exo-,3-dimethylbicyclo[2.2.1]heptan-2-ol (19) 
86  
87   
88  
Prepared as per general procedure B using 3-exo-ethyl,3-
methylbicyclo[2.2.1]heptan-2-one (4.25g, 27.92 mmol), 
methyllithium (1.6M in diethylether, 34.9 mL, 55.84 mmol) 
and THF (80 mL) to yield the title compound as a clear oil. 
(4.32 g, 92%). 
89  
IR υmax (cm-1): 3455, 2953, 2875, 1454, 1370, 1292, 1199, 
1148, 1003, 899, 876 
1H NMR (CDCl3, 400 MHz): δ (ppm) 0.86 (t, J = 7.50Hz, 3H, 
H9), 0.89 (s, 3H, H10), 1.11-1.16 (m, 1H, H7a), 1.25 (s, 3H, 
H11), 1.26-1.36 (m, 2H, H5a, H6a), 1.38 (q, J = 7.5 Hz, 2H, 
H8), 1.60-1.69 (m, 2H, H7b, H6b), 1.81-1.90 (m, 1H, H5b), 
1.94-1.98 (m, 1H, H4), 2.02-2.06 (m, 1H, H1).    
13C NMR (CDCl3, 100 MHz): δ (ppm) 9.7 (CH3, C9), 17.0 (CH3, 
C10), 20.6 (CH2, C5), 23.7 (CH2, C6), 25.3 (CH3, C11), 29.5 
(CH2, C8), 34.1 (CH2, C7), 43.7 (CH, C4), 44.4 (q, C3), 50.7 (CH, 
C1), 79.2 (q, C2).  
HRMS: (m/z - CI) calcd. for C11H21O (M+H)
+ 169.1592, found 
169.1592. 
90  
2-Azido-3-exo-ethyl-2-endo-,3-dimethylbicyclo[2.2.1] 
heptane (20) 
91  
92   
93  
Prepared as per general procedure C using 3-exo-ethyl-2-
exo-,3-dimethylbicyclo[2.2.1]heptan-2-ol (500 mg, 2.98 
mmol), 50% H2SO4 (10 mL), NaN3 (2.40 g, 36.9 mmol) and 
CHCl3 (50 mL) with a reaction time of 8 hours to yield 2-
azido-3-exo-ethyl-2,3-dimethylbicyclo[2.2.1]heptane as a 
clear oil (304 mg, 53%) and a related azide tentatively 
assigned as 2-azido-2-endo-,3-dimethylbicyclo[2.2.1]heptane  
as a clear oil (140 mg, 28%). 
94  
2-azido-3-exo-ethyl-2-endo-,3-dimethylbicyclo[2.2.1]heptane 
(20): 
95  
IR υmax (cm-1): 2917, 2849, 2087, 1463, 1378, 1131. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 0.87 (s, 3H, H10), 0.88 
(t, J = 7.38 Hz, 3H, H9), 1.11-1.14 (m, 1H, H7a), 1.28-1.35 (m, 
4H, H5a, H11), 1.39-1.60 (m, 5H, H8, H6, H5b), 1.94-1.97 (m, 
1H, H4), 1.98-2.02 (m, 1H, H7b), 2.15-2.18 (m, 1H, H1). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 10.1 (CH3, C9), 17.7 
(CH3, C11), 19.3 (CH3, C10), 23.0 (CH2, C6) 24.2 (CH2, C5), 
30.7 (CH2, C8), 34.9 (CH2, C7), 46.1 (CH, C4), 46.5 (q, C3), 48.7 
(CH, C1), 73.7 (q, C2). 
HRMS: (m/z - ES) calcd. for C11H20N (M+H-N2)
+ 166.1596, 
found 166.1596. 
 
 2-Azido-2-endo-,3-dimethylbicyclo[2.2.1]heptane (21):  
96  
97  
98  
IR υmax (cm
-1): 2965, 2879, 2082, 1458, 1261, 1111, 1079, 
741. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 0.92 (d, J = 7.41 Hz, 3H, 
H8), 1.25 (s, 3H, H9), 1.26-1.48 (m, 5H, H7a, H5, H6), 1.77-
1.83 (m, 1H H7b), 1.91-2.00 (m, 1H, H3), 2.11-2.17 (m, 2H, 
H4, H1). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 12.13 (CH3, C8), 17.6 
(CH3, C9), 20.1 (CH2, C5), 24.0 (CH2, C6), 37.2 (CH2, C7), 42.7 
(CH, C4), 44.6 (CH, C3), 48.0 (CH, C1), 69.6 (q, C2).  
 
 3-exo-Ethyl-2-endo-,3-dimethylbicyclo[2.2.1]heptan-2-
amine (22) 
99  
Page 10 of 11Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
P
ub
li
sh
ed
 o
n 
25
 O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
by
 T
ri
ni
ty
 C
ol
le
ge
 D
ub
li
n 
on
 2
5/
10
/2
01
6 
10
:4
3:
07
. 
View Article Online
DOI: 10.1039/C6OB01974A
Journal Name  COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 11  
Please do not adjust margins 
Please do not adjust margins 
100  
101  
Prepared as per general procedure D using 2-azido-3-exo-
ethyl-2-endo-,3-dimethylbicyclo[2.2.1]heptane (150 mg, 0.78 
mmol), lithium aluminium hydride solution (2 M in THF, 500 
µL, 1 mmol) and anhydrous THF (5 mL) to yield the title 
compound as a clear oil (110 mg, 84%). 
102  
IR υmax (cm
-1): 2960, 2937, 2874, 1463, 1379, 805. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 0.83 (s, 3H, H10), 0.86 
(t, J = 7.31 Hz, 3H, H9), 1.02-1.10 (m, 4H, H11, H7a), 1.21-
1.58 (m, 6H, H5, H6, H8), 1.73-1.79 (m, 1H, H1), 1.82-1.90 
(m, 1H, H7b), 1.92 (br s, 1H, H4). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 10.6 (CH3, C9), 19.3 
(CH3, C10), 23.6 (CH3, C11), 23.7 (CH2, C6), 23.9 (CH2, C5), 
29.7 (CH3, C8), 34.4 (CH2, C7), 45.2 (q, C3), 45.5 (CH, C4), 52.7 
(CH, C1), 60.6 (q, C2). 
HRMS: (m/z - ES) calcd. for C11H22N (M+H)
+ 168.1752, found 
168.1751. 
 
 3-ethyl-N,2,3-trimethylbicyclo[2.2.1]heptan-2-aminium 
chloride (24.HCl) 
103  
104  
105  
Prepared as per general procedures E and F using 3-exo-
ethyl-2-endo-,3-dimethylbicyclo[2.2.1]heptan-2-amine (120 
mg, 0.62 mmol), paraformaldehyde (70 mg, 2.33 mmol), 
molecular sieves (200 mg), CH2Cl 2 (5 mL) and sodium 
borohydride (110 mg, 2.91 mmol) to yield the desired amine 
as a viscous oil. This oil was dissolved in anhydrous diethyl 
ether (1.0 mL) and hydrogen chloride solution (2 M in 
diethylether, 800 μL, 1.6 mmol) was added. The desired HCl 
salt was obtained by filtration and dried under vacuum to 
yield a white solid (80 mg, 59%). 
106  
IR υmax (cm
-1): 3359, 2953, 1457, 1370, 1150, 1112, 914, 892. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 0.94 (t, J = 7.0 Hz, 3H, 
H9), 0.98 (s, 3H, H10), 1.5 (d, J = 11.4 Hz, 1H, H7a), 1.34-1.60 
(m, 7H, H5, H6, H11), 1.78-1.90 (m, 1H, H8a), 2.03-2.14 (m, 
1H, H8b), 2.20-2.23 (m, 1H, H4), 2.35 (d, J = 11.4 Hz, 1H, 
H7b), 2.39-2.43 (m, 1H, H1), 2.69 (br s, 3H, H12), 8.40 (br s, 
1H, H13a), 9.00 (br s, 1H, H13b). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 10.0 (CH3, C9), 16.0 
(CH3, C11), 19.1 (CH3, C10), 23.1 (CH2, C5), 23.4 (CH3, C6), 
27.9 (CH2, C8), 29.0 (CH3, C12), 34.5 (CH2, C7), 44.1 (CH, C4), 
44.7 (CH, C1), 47.6 (q, C3), 71.5 (q, C2) 
HRMS: (m/z - ES) calcd. for C12H24N (M
+) 182.1909, found 
182.1911. 
 
Biological testing 
 
Xenopus oocyte expression and electrophysiological 
recordings 
107   
Stage V and VI Xenopus oocytes were prepared as previously 
described.35,36 Wild-type α4 or β2 subunit cDNAs, ligated 
into the pCI (Promega) expression vector, were dissolved in 
distilled water at a concentration of 1 µg/µL 
(spectrophotometric and agarose gel electrophoresis 
determinations). Mixtures of wild-type α4 and β2 cDNA at 
1:1 ratios were injected into the nuclei of oocytes in a 
volume of  18.4 nL/oocyte, using a Nanoject Automatic 
Oocyte Injector (Drummond, Broomall, PA, U.S.A.). The total 
amount of cDNA injected per oocyte was kept constant at 2 
ng. After injection oocytes were incubated at 18 °C for 2-5 
days in a modified Barth’s solution containing 88 mM NaCl, 1 
mM KCl, 2.4 mM NaHCO3, 0.3 mM Ca(NO3)2, 0.41 mM CaCl2, 
0.82 mM MgSO4, 15 mM Hepes and 5 mg/L neomycin (pH 
7.6) Recordings were performed  3 - 5 days post-injection.  
108 Oocytes were placed in a 0.1 mL recording chamber and 
perfused with modified Ringer solution (in mM: NaCl 150, 
KCl 2.8, Hepes 10, BaCl2 1.8; pH 7.2, adjusted with NaOH) at 
a rate of 10 mL/min. We chose a nominally Ca2+ free solution 
in order to minimise the contribution to the response of 
Ca2+-gated chloride channels which are endogenous to the 
Xenopus oocyte and may be activated by Ca2+ entry through 
the nAChRs, as previously reported.35 
Oocytes were impaled by two agarose-cushioned 
microelectrodes filled with 3 M KCl (0.5-2.0 MΩ) and 
voltage-clamped at –60 mV using a Geneclamp 500B 
amplifier (Axon Instruments, CA, U.S.A.). All experiments 
were carried out at room temperature. A minimum interval 
of 4 minutes was allowed between acetylcholine applications 
as this was found to be sufficient to ensure reproducible 
recordings. The sensitivity of the receptors to inhibition by 
the novel nAChR antagonists (3 μM) was tested by first 
superfusing the antagonist for 2 min and then coapplying it 
with an  EC50 of ACh (α4β2 nAChR EC50:  100 μM) 
109  
SH-SY5Y cells (passages 19 to 28) were cultured in an 
incubator at 37°C and 5% CO2.
37 Cells were maintained in 
Advanced DMEM/F-12 medium supplemented with 2% FBS, 
2mM L-glutamine, 190 U/mL penicillin and 0.2mg/mL 
streptomycin. For assays, cells were plated in 96 well plates 
(Falcon) and grown under the same culture conditions until 
confluent before being used. 
Ca2+ response assay Cells in 96 well plates were washed 
twice with TSS (137mM NaCl, 2.7mM KCl, 1mM MgCl2, 
1.8mM CaCl2, 0.2mM NaH2PO4, 12mM NaHCO3, 5.5mM 
glucose; pH 7.4). Cells were then incubated in TSS with 10μM 
fluo-3 AM and 0.02% pluronic acid for 1 hour, at room 
temperature in the dark. Cells were washed twice more with 
TSS and left in 80μL TSS. For inhibitor pre-incubations, the 
80μL TSS was replaced with 80μL TSS containing appropriate 
drug concentrations. All drugs were pre-incubated at room 
temperature in the dark 10 for 10 minutes, except for CdCl2 
which was pre-incubated for 15 minutes. Four replicate wells 
were used per condition in each assay. Stimulation drugs, 
either 100μM (-)-nicotine hydrogen tartrate or 100mM KCl, 
were added in 20μL TSS and fluorescence was measured 
(485nm excitation, 538nm emission) using a Fluoroskan 
Ascent plate reader and Ascent software (Labsystems). 
Maximum (Fmax) and minimum (Fmin) fluorescence values for 
each well were obtained by taking readings after adding 1% 
Triton X-100 and 350mM MnCl2 respectively (both in TSS). 
These measurements were used to calculate Fmax-Fmin, and 
assay results were normalised as a percentage of Fmax-Fmin. 
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